Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.

Karissa M Johnston Lauren C Powell Evan PopoffGil J L'ItalienRobert Pawinski Aideen Ahern Sam Large Thang Tran Aaron Jenkins

Published in: Journal of medical economics (2024)

This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.

Keyphrases

liver failure
healthcare
respiratory failure
palliative care
drug induced
quality improvement
cross sectional
intensive care unit
pain management
chronic pain
extracorporeal membrane oxygenation
life cycle